Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
Protein Networks02:26

Protein Networks

3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HinZip: Combining Hin Recombinase and FosW to Mimic HD-Zip Plant Proteins.

ACS synthetic biology·2025
Same author

Designer Frankenproteins That Halt the Proliferation of Myc-Driven Cancer Cells.

Journal of medicinal chemistry·2025
Same author

Unlocking genetic potential: harnessing phage for targeted mutagenesis in phage-assisted evolution.

Nucleic acids research·2025
Same author

Beyond small molecules: advancing MYC-targeted cancer therapies through protein engineering.

Transcription·2025
Same author

Combining a Base Deaminase Mutator with Phage-Assisted Evolution.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

Combining Rational Design and Continuous Evolution on Minimalist Proteins That Target the E-box DNA Site.

ACS chemical biology·2020

Related Experiment Video

Updated: May 20, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.7K

Targeting MYC with protein drugs.

Jumi A Shin1

  • 1Department of Chemistry, University of Toronto, Mississauga, ON, Canada.

Progress in Molecular Biology and Translational Science
|March 23, 2025
PubMed
Summary

Protein drugs show promise for targeting the MYC oncogene, a key driver in many cancers. Omomyc, a protein drug, has successfully inhibited solid tumors, offering a new strategy against MYC-driven cancers.

Keywords:
E-box response elementIntrinsically disordered protein structureLipid nanoparticle (LNP)LiposomeMAXME47MEFMSin3AMYCMadOmomycSID moduleTranscription factor

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

5.9K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Related Experiment Videos

Last Updated: May 20, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.7K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

5.9K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Cancer remains a leading cause of death globally, with limited therapeutic options beyond small molecules.
  • The MYC proto-oncogene, implicated in most human cancers, is a critical target for novel cancer therapies.
  • Current treatments struggle to effectively target MYC due to its intracellular and genomic interactions.

Purpose of the Study:

  • To explore the potential of protein drugs as next-generation therapeutics against the MYC oncogene.
  • To highlight the efficacy of Omomyc, a protein drug, in inhibiting MYC-driven solid tumors.

Main Methods:

  • Investigated the mechanism of action for protein drugs targeting intracellular MYC.
  • Evaluated the therapeutic potential of Omomyc in preclinical and clinical settings for solid tumors.

Main Results:

  • Protein drugs can function within the cell nucleus to interact with the genome or MYC.
  • Omomyc demonstrated successful inhibition of solid tumors in human trials, unlike small-molecule drugs targeting MYC.
  • MYC's role as a crucial regulator necessitates new containment strategies when dysregulated.

Conclusions:

  • Protein drugs represent a promising frontier for developing novel cancer therapies targeting MYC.
  • Omomyc offers a viable therapeutic strategy for cancers driven by aberrant MYC activity.
  • Further development of protein-based therapeutics is crucial for advancing cancer treatment.